Hypertensive disorders of pregnancy are a major cause of maternal and perinatal mortality. Preeclampsia, typically arising after 20 weeks of gestation, involves new-onset hypertension, often with proteinuria, and can progress to severe forms like eclampsia and HELLP syndrome. It usually begins as gestational hypertension. Early diagnosis and timely management are critical to reducing risks for both mother and baby.
<h3 dir="ltr">Epidemiology Segmentation</h3>
<ul>
<li dir="ltr" aria-level="1">
Total Incidence Cases of Preeclampsia
</li>
<li dir="ltr" aria-level="1">
Total Diagnosed Incidence Cases of Preeclampsia
</li>
<li dir="ltr" aria-level="1">
Age-specific Cases of Preeclampsia
</li>
<li dir="ltr" aria-level="1">
Sub-type specific Cases of Preeclampsia
</li>
<li dir="ltr" aria-level="1">
Severity specific Cases of Preeclampsia
</li>
<li dir="ltr" aria-level="1">
Treated Cases of Preeclampsia
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/preeclampsia-epidemiology-forecast">Preeclampsia Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, DelveInsight estimated ~334K diagnosed preeclampsia cases in the 7MM, with the U.S. accounting for ~220K.
</li>
<li dir="ltr" aria-level="1">
In the U.S., the 25&ndash;29 and 30&ndash;34 age groups reported ~66K and ~63K cases, respectively.
</li>
<li dir="ltr" aria-level="1">
Germany led the EU4 and UK with ~26K cases, followed by France with ~25K.
</li>
<li dir="ltr" aria-level="1">
The U.S. also had the highest number of late-onset (~260K) and early-onset (~30K) cases.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/preeclampsia-market">Preeclampsia Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
The preeclampsia market in the 7MM reached ~USD 80 million in 2024, with the U.S. contributing ~USD 70 million.
</li>
<li dir="ltr" aria-level="1">
Germany and France led the EU4 and UK with ~USD 4 million combined.
</li>
<li dir="ltr" aria-level="1">
No approved therapies exist; management relies on antihypertensives, anticonvulsants, and corticosteroids.
</li>
<li dir="ltr" aria-level="1">
Antihypertensives dominated the U.S. market, generating ~USD 50 million in 2024.
</li>
</ul>
<h3 dir="ltr">Preeclampsia Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
A significant number of cases globally, especially in the U.S., continues to drive demand for improved treatments.
</li>
<li dir="ltr" aria-level="1">
Increased clinical focus on novel therapies and biomarkers is fueling R&amp;D investments.
</li>
<li dir="ltr" aria-level="1">
Improved screening and prenatal care are enabling earlier intervention and better management.
</li>
</ul>
<h3 dir="ltr">Preeclampsia Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
No disease-specific approved treatment exists; delivery remains the only definitive solution.
</li>
<li dir="ltr" aria-level="1">
Current management is limited to symptom control, restricting therapeutic innovation.
</li>
<li dir="ltr" aria-level="1">
Regulatory and ethical complexities in conducting trials during pregnancy hinder drug development.
</li>
</ul>
<h3 dir="ltr">Preeclampsia Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
Diabetomics, Inc.
</li>
<li dir="ltr" aria-level="1">
Metabolomic Diagnostics Ltd.
</li>
<li dir="ltr" aria-level="1">
Sera Prognostics
</li>
<li dir="ltr" aria-level="1">
Thermo Fisher Scientific Inc.
</li>
<li dir="ltr" aria-level="1">
Siemens Healthineers AG
</li>
<li dir="ltr" aria-level="1">
Bayer AG
</li>
</ul>
And others.

Preeclampsia Market Infographic

Preeclampsia Market Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.